A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds

Abstract Background Protection against contemporary severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants requires sequence-adapted vaccines. Methods In this ongoing phase 2/3 trial, 12–17-year-olds (n = 108), 18–55-year-olds (n = 313), and >55-year-olds (n = 306) who previously r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical infectious diseases 2024-05, Vol.78 (5), p.1194-1203
Hauptverfasser:	Usdan, Lisa, Patel, Sohil, Rodriguez, Hector, Xu, Xia, Lee, Dung-Yang, Finn, Daniel, Wyper, Hayley, Lowry, Francine S, Mensa, Federico J, Lu, Claire, Cooper, David, Koury, Kenneth, Anderson, Annaliesa S, Türeci, Özlem, Şahin, Uğur, Swanson, Kena A, Gruber, William C, Kitchin, Nicholas
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Antibodies, Neutralizing - blood Antibodies, Neutralizing - immunology Antibodies, Viral - blood BNT162 Vaccine - administration & dosage BNT162 Vaccine - immunology Child COVID-19 - immunology COVID-19 - prevention & control COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - immunology Female Humans Immunization, Secondary Immunogenicity, Vaccine Major Male Middle Aged SARS-CoV-2 - immunology Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!